The CNETS Canada Neuroendocrine Tumour Research Grant provides each calendar year grant-in-aid for two projects up to a maximum of $40,000 per project. The NET research funding priorities were determined through consultation with the NET patient community, and input from CNETS Canada’s Scientific and Medical Advisory Board (SMAB). To be eligible for the 2017 NET Research Grant, it was determined that the project must be a clinical trial or a clinical or fundamental research project (including animal or cellular models) to examine issues relevant for the diagnosis and treatment of Neuroendocrine tumors (NETs).
In 2017 CNETS Canada received eight applications for NET cancer research projects in Canada, an excellent level of interest and reflects the growing number of clinicians and centres with a focus on NET cancers. The review and recommendation process was carried out by a Grant Review Committee, chaired by CNETS Canada Scientific & Medical Advisory Board Co-Chairs, Dr. Girish Shah and Dr. Jean-Luc Urbain. Additional panel member included one patient, three members of the CNETS Canada Scientific & Medical Advisory Board, in addition to an oncologist and a radiologist from within the Canadian NET community. Proposals were assessed on medical and scientific merits and overall value proposition and the ultimate granting decision was made by the CNETS Canada Board of Directors.
The two 2017 Neuroendocrine Tumour Research Grant Recipients are focusing on the areas of lung NETs and immunotherapy for high grade NEC patients. Dr. Philippe Joubert from Quebec Heart & Lung Institute (IUCPQ) – Université Laval, will work on “Comprehensive clinical and molecular characterization of diffuse idiopathic pulmonary neuroendocrine cells hyperplasia (DIPNECH)” . The second recipient is Dr. Simron Singh from Sunnybrook Health Sciences Centre, who will focus on “Predicting response to immunotherapy in neuroendocrine carcinoma”.